Impact of Smoking Status on Hospital Outcome of Patients with ST-Segment Elevation Myocardial Infarction Either Treated by Pharmaco-Invasive Strategy or Primary Percutaneous Coronary Intervention  

作　　者：Ahmed F. Alaarag Mahmoud A. Abouomar Timoor M. Hassan Ahmed F. Alaarag;Mahmoud A. Abouomar;Timoor M. Hassan(Cardiology Department, Tanta University, Tanta, Egypt)

机构地区：[1]Cardiology Department, Tanta University, Tanta, Egypt

出　　处：《World Journal of Cardiovascular Diseases》2020年第6期347-356,共10页心血管病（英文）

摘　　要：<strong>Introduction:</strong> <span style="font-family:Verdana;">Smoking is a common public problem with a high health burden. Many studies have shown that there are many hazardous actions of smoking on body systems especially haemostatic, respiratory and circulatory systems.</span><span style="font-family:Verdana;"> </span><span style="font-family:Verdana;">Smoking may increase the thrombus burden in patients with acute coronary syndrome. The </span><span style="font-family:Verdana;">“</span><span style="font-family:Verdana;">smoker’s paradox</span><span style="font-family:Verdana;">”</span><span style="font-family:Verdana;"> has been described for more than 25 years. Its existence and its effect on patients’ outcome post-myocardial infarction are debatable</span><span style="font-family:Verdana;">. </span><span style="font-family:Verdana;"><b>Methods: </b></span><span style="font-family:Verdana;">Our prospective observational study was conducted from-August 2018 to August 2019 on STEMI patients with the duration from onset of symptoms to first medical contact were 12 hours or less. We included 199 patients in our study.</span><span style="font-family:Verdana;"> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">Patients are divided into 4 groups </span><b><i><u><span style="font-family:Verdana;">Group </span></u></i><u><span style="font-family:Verdana;">1</span></u></b></span><span style="font-family:Verdana;"><b> </b></span><span style="font-family:;" "=""><span style="font-family:Verdana;">(Smokers treated by PPCI) </span><b><i><u><span style="font-family:Verdana;">Group </span></u></i><u><span style="font-family:Verdana;">2</span></u></b><span style="font-family:Verdana;"> (Non-smokers treated by</span></span><span style="font-family:;" "=""><span style="font-family:Verdana;"> PPCI) </span><b><i><u><span style="font-family:Verdana;">Group </span></u></i><u><span style="font-family:Verdana;">3</span></u></b><span style="font-family:Verdana;"> (Smoker treated by pharmaco-inva<strong>Introduction:</strong> <span style="font-family:Verdana;">Smoking is a common public problem with a high health burden. Many studies have shown that there are many hazardous actions of smoking on body systems especially haemostatic, respiratory and circulatory systems.</span><span style="font-family:Verdana;"> </span><span style="font-family:Verdana;">Smoking may increase the thrombus burden in patients with acute coronary syndrome. The </span><span style="font-family:Verdana;">“</span><span style="font-family:Verdana;">smoker’s paradox</span><span style="font-family:Verdana;">”</span><span style="font-family:Verdana;"> has been described for more than 25 years. Its existence and its effect on patients’ outcome post-myocardial infarction are debatable</span><span style="font-family:Verdana;">. </span><span style="font-family:Verdana;"><b>Methods: </b></span><span style="font-family:Verdana;">Our prospective observational study was conducted from-August 2018 to August 2019 on STEMI patients with the duration from onset of symptoms to first medical contact were 12 hours or less. We included 199 patients in our study.</span><span style="font-family:Verdana;"> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">Patients are divided into 4 groups </span><b><i><u><span style="font-family:Verdana;">Group </span></u></i><u><span style="font-family:Verdana;">1</span></u></b></span><span style="font-family:Verdana;"><b> </b></span><span style="font-family:;" "=""><span style="font-family:Verdana;">(Smokers treated by PPCI) </span><b><i><u><span style="font-family:Verdana;">Group </span></u></i><u><span style="font-family:Verdana;">2</span></u></b><span style="font-family:Verdana;"> (Non-smokers treated by</span></span><span style="font-family:;" "=""><span style="font-family:Verdana;"> PPCI) </span><b><i><u><span style="font-family:Verdana;">Group </span></u></i><u><span style="font-family:Verdana;">3</span></u></b><span style="font-family:Verdana;"> (Smoker treated by pharmaco-inva

关 键 词：Smoker Paradox STEMI Primary PCI Pharmaco-Invasive Strategy 

分 类 号：R54[医药卫生—心血管疾病]